Glaukos is an ophthalmic medical technology company focused on the development and commercialisation of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness.
Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) in order to revolutionise the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012. In 2016 Glaukos Australia began direct operations and launched its next-generation technology, the iStent inject. According to Glaukos, the iStent inject is the smallest medical device ever approved by the Therapeutic Goods Administration, measuring 0.36mm long and 0.23 mm wide.
Contact: Glaukos (AUS) 03 9832 0610 or visit www.glaukos.com